Ottawa Fertility Center, 955 Green Valley Crescent, Ottawa Ontario K2C 3V4, Canada.
Reprod Biomed Online. 2022 Aug;45(2):211-218. doi: 10.1016/j.rbmo.2022.03.024. Epub 2022 Apr 1.
Spermatozoa can be recovered in half of patients with non-obstructive azoospermia (NOA) via testicular sperm extraction (TESE) or microTESE. Intracytoplasmic sperm injection (ICSI) with the recovered spermatozoa has been established at IVF clinics to help these patients. Those who fail to achieve spermatozoa in testicular samples usually turn to donor spermatozoa or adoption. Instead of spermatozoa, only round spermatids are present in testicular biopsy in some NOA patients, a form of globozoospermia. Of these men, those who are unwilling to use donor spermatozoa still have the option to have their own biological child. In recent years, round spermatid injection (ROSI) has been developed as a potential option, with about 100 healthy babies born. However, the outcomes have so far been poor, with low pregnancy rates. One reason for this could be oocyte activation deficiency (OAD). Different from regular ICSI, round spermatids after ROSI do not induce calcium oscillation, which is critical for later oocyte activation and embryo development. Therefore, optimal assisted oocyte activation (AOA) stimulation is needed to mimic the physiological events. So far, a number of methods have been examined, including vigorous cytoplasm aspiration, calcium chloride injection, calcium ionophore treatment and electroporation. Over 100 healthy babies have been born, with no developmental or physiological abnormalities compared with regular children or those born from IVF and ICSI procedures, although some studies have found epigenetic modification. More recent studies have shown that electroporation for AOA has more credits than those tested so far. The overall positive outcome of ROSI is still poor and unstable, so it has not become a routine procedure in IVF clinics. Success rates would be improved with further optimization of AOA to enable patients to have their own genetic offspring.
通过睾丸精子提取(TESE)或 microTESE,可在一半的非梗阻性无精子症(NOA)患者中回收精子。已经在体外受精(IVF)诊所中建立了使用回收精子的胞浆内精子注射(ICSI),以帮助这些患者。那些在睾丸样本中未能获得精子的患者通常会转向使用供精或收养。在一些 NOA 患者的睾丸活检中,除了精子之外,只有圆形精原细胞存在,这是一种球形精子症。对于这些男性来说,如果不愿意使用供精者,他们仍然有机会拥有自己的亲生子女。近年来,圆形精原细胞注射(ROSI)已被开发为一种潜在的选择,已有约 100 名健康婴儿出生。然而,到目前为止,结果并不理想,妊娠率低。原因之一可能是卵母细胞激活缺陷(OAD)。与常规 ICSI 不同,ROSI 后的圆形精原细胞不会诱导钙震荡,这对后期卵母细胞激活和胚胎发育至关重要。因此,需要进行最佳的辅助卵母细胞激活(AOA)刺激,以模拟生理事件。到目前为止,已经检查了多种方法,包括剧烈细胞质抽吸、氯化钙注射、钙离子载体处理和电穿孔。已经有 100 多名健康婴儿出生,与常规儿童或通过 IVF 和 ICSI 程序出生的儿童相比,没有发育或生理异常,尽管一些研究发现了表观遗传修饰。最近的研究表明,用于 AOA 的电穿孔比迄今为止测试的方法更有优势。ROSI 的总体积极结果仍然较差且不稳定,因此它尚未成为 IVF 诊所的常规程序。通过进一步优化 AOA,可以提高成功率,使患者能够拥有自己的遗传后代。